Insulin resistance related to obesity and diabetes is characterized by an increase in plasma TG-rich lipoprotein concentrations. Apolipoprotein (apo) E plays a crucial role in the metabolism of these lipoproteins and particularly in the hepatic clearance of their remnants. The aim of this study was to explore apoE kinetics of obese subjects and to determine what parameters could influence its metabolism. METHODS: Using stable-isotope labelling technique ([ 2 H 3 ]-leucine-primed constant infusion) and monocompartmental model (SAAM II computer software), we have studied the plasma kinetics of very-low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) apoE in 12 obese subjects (body mass index (BMI) 27.4 -36.6 kg=m 2 ): Seven were type 2 diabetics (age 47 -65 y; HbA1c 7.1 -10.2%) and five were non-diabetics (age 40 -51 y, HbA1c: 4.9 -5.3%). Six of the diabetic subjects were insulin resistant as assessed by insulin sensitivity index (HOMA 2.6 -10.0), while non-diabetic subjects were all insulin sensitive (HOMA 1.2 -2.1). RESULTS: Plasma VLDL and HDL apoE concentrations were significantly higher in diabetic than in non-diabetic subjects (5.74 AE 1.60 vs 1.46 AE 1.74 mg=l, P < 0.01 and 17.81 AE 6.67 vs 9.97 AE 3.32 mg=l, P < 0.05). These increased levels were associated with significantly higher absolute production rate (APR) of VLDL and HDL apoE (0.714 AE 0.343 vs 0.130 AE 0.200 mg=kg=day, P < 0.01, and 0.197 AE 0.087 vs 0.080 AE 0.060 mg=kg=day, P < 0.05, respectively) while no significant difference was found for fractional catabolic rate (FCR) of VLDL and HDL apoE (3.44 AE 1.64 vs 1.97 AE 0.84=day and 0.30 AE 0.12 vs 0.19 AE 0.09=day, respectively). In the whole population, BMI was not correlated with any of apoE kinetic data. HOMA was positively correlated with FCR of VLDL apoE (r ¼ 0.64, P < 0.05) and tended to be correlated with APR of VLDL apoE (r ¼ 0.58, P ¼ 0.06). HbA1c was positively correlated with APR and FCR of both VLDL apoE (r ¼ 0.91 and 0.78, P < 0.01, respectively) and HDL apoE (r ¼ 0.66 and 0.69, P < 0.05, respectively). CONCLUSION: Obese diabetics are characterized by elevated VLDL and HDL apoE levels associated with enhancement of VLDL and HDL apoE production rates. Whereas obesity did not influence apoE kinetic parameters in itself, insulin resistance may lead to an increase in VLDL apoE production and fractional catabolic rates. Diabetes and the glycemic control may also specifically influence the kinetics of both VLDL and HDL apoE. All together, these disorders should explain at least part of the increase in VLDL and HDL apoE observed in diabetes.
Introduction
Obesity and diabetes are major risk factors for coronary heart disease (CHD). 1, 2 Both are closely related and obesity is an important predictor of diabetes. 3, 4 The key factor linking obesity with glucose intolerance and dyslipidemia, leading further to type 2 diabetes, is insulin resistance syndrome. 5 Actually, this so-called 'X syndrome', introduced by Reaven in 1988, 6 is partly responsible for the increased risk of CHD in obese and diabetic subjects. 5, 7 Hyperinsulinemia, glucose intolerance, elevated blood pressure, high plasma triglyceride (TG) rich lipoproteins level (very-low-density lipoproteins, VLDL) and reduced circulating level of high-density lipoprotein (HDL) cholesterol are some of the clinical and biological abnormalities clustering with insulin resistance. 5 -7 Apolipoprotein (apo) E is found in VLDL and HDL and plays a central role in both lipoprotein metabolisms. This protein has been shown to be necessary for the conversion of VLDL towards IDL (intermediate density lipoprotein) and LDL (low density lipoprotein). 8 ApoE also mediates the direct hepatic clearance of VLDL and their remnants via its hepatic receptors, eg LDL-R (LDL-receptor) and LRP (LDL related receptor). 8, 9 Its role, modulating the catabolism of these apoB-containing lipoproteins, has been demonstrated in animals 10, 11 and in human. 8,12 -14 Some recent studies have also demonstrated a role for apoE in hepatic VLDL apoB 15 and TG secretion. 16 Furthermore, cellular and animal studies have pointed out the crucial role of apoE in HDL catabolism, mediating HDL clearance through its hepatic receptors. 17, 18 ApoE is highly exchangeable between lipoproteins and is transferred from HDL-to TG-rich lipoproteins. 19 After lipolysis by lipoprotein lipase and hepatic lipase, apoE is again transferred to HDL. 12, 20 Thus, relative distribution of apoE between VLDL and HDL is related to lipolytic cascade and may influence cholesterol and TG clearance. This is an important point since lipoprotein lipase activity is inversely correlated with insulin resistance degree and hyperinsulinemia 21 and since obesity and insulin resistance are potentially associated with a redistribution of apoE between apoB and non apoB containing lipoproteins. 22, 23 This study was realized to determine apoE kinetics during hypertriglyceridemic state associated with insulin resistance syndrome related to obesity and type 2 diabetes and to define what parameters may influence apoE kinetics in these patients.
Materials and methods

Subjects and study protocol
Kinetic studies of apoE metabolism were performed in 12 Caucasian obese volunteers, including five healthy (three men, two women, 40 -51 y, mean 46 y) and seven type 2 diabetic subjects (four men, three women, 47 -65 y, mean 55 y). Among diabetic patients, six were insulin-resistant as assessed by insulin sensitivity index (homeostasis model assessment (HOMA) > 2.5, a mathematical estimate of insulin sensitivity based on fasting glucose and insulin concentrations: HOMA ¼ glucose * insulin=22.5). 24 None was engaged in any type of exercise programme or was excessively sedentary. None was suffering from infection as assessed by clinical examination, platelets and leucocyte formulation. None had taken any medication that could affect lipid for at least 2 months before study. All women were postmenopausal. Diabetic patients had no proteinuria or hypothyroidism, and were not regularly cigarette smokers or alcohol consumers. They were not treated with insulin. Study subjects were instructed by a dietician to eat a weightmaintenance iso-energetic diet composed of 50% of the usual daily energy intake as carbohydrate, 35% as fat and 15% as protein, for at least 3 months before the study. The Ethical Committee of Nantes University Hospital approved the experimental protocol, and informed consent was obtained before the study was started.
Endogenous labelling of apoE was performed by administration of L- [5,5,5- 2 H 3 ]-leucine (99.8 Atom% 2 H 3 ; Cambridge Isotope Laboratories, Andover, MA, USA), dissolved in a 0.9% saline solution and tested for sterility and absence of pyrogens before the study. All subjects fasted overnight for 12 h before the study, and remained fasting during the entire protocol. Each subject received intravenously a prime of 10 mmol=kg of tracer, immediately followed by a constant tracer infusion (10 mmol=kg=h) for 14 h. Venous blood samples were withdrawn in EDTA tubes (Venoject, Paris, France) at baseline, every 15 min during the first hour, every 30 min during the next 2 h, and then hourly until the end of the study. Plasma was immediately separated by centrifugation for 30 min at 4 C. Sodium azide, an inhibitor of bacterial growth, and Pefabloc SC (Interchim, Montluçon, France), a protease inhibitor, were added to blood samples at a final concentration of 1.5 and 0.5 mmol=l, respectively.
Analytical methods
Measurement, isolation and preparation of apolipoproteins. VLDL (d < 1.006 g=ml), were isolated from 3 ml of plasma by a sequential ultracentrifugation using an angle rotor (RPS 40T, Kontron Instruments, Montigny-LeBretonneux, France) at 40 000 rpm for 24 h at 10 C (Centrikon T-2070, Kontron Instruments, Montigny-Le-Bretonneux, France). HDL (1.063 < d < 1.210 g=ml) were then isolated by a density gradient ultracentrifugation modified method, 25 using a swinging bucket rotor (RPS 55T, Kontron Instruments, Montigny-Le-Bretonneux, France) at 40 000 rpm for 24 h at 10 C (Centrikon T 2060, Kontron Instruments, Montigny-LeBretonneux, France). Blood glucose, cholesterol, TG and HDLcholesterol were assayed enzymatically using a multiparametric analyser (Hitachi 747, Roche Molecular Biochemicals, Meylan, France). LDL-cholesterol was calculated with the Friedewald formula. 26 Serum insulin concentrations were measured using commercial RIA kits (Bi-Insulin IRMA; ERIAPasteur, Paris, France). Total serum apoE, VLDL and HDL apoE levels were measured by electroimmunoassay (Sebia, Issy-lesMoulineaux, France). Coefficients of variation for the assay were less than 8%. ApoAI and apoB levels were measured in plasma by immunonephelometry (Dade-Behring, Rueil Malmaison, France).
ApoE phenotyping was determined on plasma delipidated with ethanol=ether (3:1, v=v) by preparative isoelectric focusing (IEF) on 7.5% polyacrylamide -urea (8 M) gels (pH gradient 4 -7). 27 Three of the five non-diabetic subjects were phenotyped as E3=E3 and two as E3=E2. Five of the seven diabetic subjects were phenotyped as E3=E3, one E4=E3 and one as E3=E2.
VLDL and HDL apoE were isolated by preparative gradient (4 -19%) sodium dodecylsulphate polyacrylamide Influence of insulin resistance and diabetes on apolipoprotein E kinetics K Back-Ngohou et al gel electrophoresis (SDS -PAGE). 28 As this method allows for the separation of total apoE, kinetic results in subjects with a heterozygous apoE phenotype will represent the weighted average of the kinetics behaviours of individual isoforms in lipoprotein fractions. Apolipoprotein bands were excised from polyacrylamide gels and hydrolysed with 1 ml of 4 N HCl (Sigma, St Quentin Fallavier, France) at 110 C for 24 h. Hydrolysates were then evaporated to dryness and the amino acids purified by cation exchange chromatography using a Dowex 50WX8 ion exchange resin (Sigma, St Quentin Fallavier, France). Plasma amino acids were esterified with propanol=acetyl chloride, and further derivatized using heptafluorobutyric anhydride acid (Fluka Chemie AG, Buchs, Switzerland) before analysis. C. Electron impact -gas chromatography -mass spectrometry was performed on a 5890 series II gas chromatograph connected with a 5971 Å quadrupole mass spectrometer (Hewlett Packard, Palo Alto, CA, USA). The isotopic ratio was determined by selected ion-monitoring at m=z of 282 and 285. Calculations of apoE kinetic parameters were based on the tracer-to-tracee mass ratio. 29 For the determination of isotopic enrichment, the coefficient of variation for samples with tracer=tracee ratio less than 1.0% (HDL apoE) was 7% and decreased to 5% for samples with tracer=tracee ratio greater than 1.0% (VLDL apoE).
Determination of lipoprotein lipase (LPL) activity. Determination of LPL activity has been described previously. 30 Briefly, at the end of the tracer infusion, pre-and postheparin blood was drawn into ice-cold EDTA tubes, before and 10 min after an intravenous injection of 100 IU of heparin per kg of body weight. Plasma was separated at 4 C and stored frozen until assayed. Lipase activities were measured following the method of Iverius and Brunzell. 31 The assay was performed using glycerol tri [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]oleate (NEN Life Science Products, Boston, MA, USA) emulsified with Triton X-100 as substrate. Hepatic lipase activity was inhibited by SDS, as previously described. 32 Lipases activities were expressed in mmoles of free fatty acids hydrolysed by 1 ml of post heparin plasma in 1 h of incubation at 37 C.
Modelling. Kinetic analysis of tracer-to-tracee ratios was achieved by computer software for simulation, analysis and modelling (SAAM II version 1.0.1, Resource Facility for Kinetic Analysis, Department of Bioengineering, SAAM Institute, Seattle, WA, USA). VLDL and HDL apoE data were kinetically analysed using a mono-exponential function:
, where A(t) is the tracer-totracee ratio at time t, Ap, the tracer-to-tracee ratio of the precursor pool of apoE, d, the delay between the beginning of the experiment and the appearance of tracer in the apolipoprotein, and k the fractional production rate (FPR) of the apolipoprotein. The use of more complex models did not provide significant improvement in the fitting (F test and Akaike information criterion 33 ). The plateau enrichment of VLDL apoE was used as its own precursor and as an estimation of precursor pool enrichment for HDL apoE synthesis. This is made upon the assumption that more than 95% of plasma circulating apoE is synthesized by the liver. 34, 35 We estimated the FPR, ie the proportion of apoE entering the pool per unit time (day), and the absolute production rate (APR), ie the amount of apoE entering the pool per unit time (mg=kg=day). APR was the product of FPR multiplied by apoE mass respectively in VLDL and in HDL. ApoE pool was considered to be constant, as no significant variation was observed between measurements made at three different infusion time (data not shown). Under these steady-state conditions, FPR equals fractional catabolic rate (FCR).
Statistical analysis
Mann -Whitney U-test, performed with Statview F-4.5 (Abacus Concepts, Berkeley, CA, USA), was used to compare clinical and kinetic data between type 2 diabetic and nondiabetic subjects. Pearson linear correlation was done using SAS statistical software (SAS Institute Inc., Cary, NC, USA). For non-normally distributed variables (FCR of VLDL apoE, APR of VLDL apoE, FCR of HDL apoE, APR of HDL apoE, VLDL apoB, VLDL-cholesterol, HOMA, HbA1c, BMI, plasma TG, cholesterol and insulin levels), values were logtransformed to look at relationships between variables. A two-tailed probability level of 0.05 was accepted as statistically significant.
Results
Characteristics of subjects studied Clinical and biological characteristics of obese studied are presented in Table 1 . Plasma glucose level and HbA1c were significantly higher in type 2 diabetics compared with nondiabetics.
While plasma cholesterol and TG levels were significantly increased in diabetic patients, lipoprotein lipase (LPL) activity was significantly reduced. VLDL cholesterol was significatively increased (mean 0.83 AE 0.51 vs 0.20 AE 0.12 g=l, P ¼ 0.01) and VLDL TG tended to be higher (mean 1.27 AE 0.47 vs 0.62 AE 0.42 g=l, P ¼ 0.07) in diabetics than in non-diabetics. While plasma apoAI and total apoE levels were not significantly different between groups, total apoB and VLDL apoB levels were significantly increased in diabetic patients.
VLDL and HDL apoE levels and kinetic parameters Within 30 min of infusion, tracer-to-tracee ratios of plasma free leucine reached steady state in all study subjects. This Figure 1 . Tracer-to-tracee curve of VLDL apoE increased rapidly during the infusion period in all subjects. In diabetics, VLDL apoE enrichment increased slightly faster than it did in nondiabetic subjects. Contrasting with VLDL apoE enrichment, tracer-to-tracee curve of HDL apoE enrichment increased slowly in all subjects. HDL apoE enrichment reached approximatively 1% after 14 h of infusion. Similarly to VLDL apoE enrichment, tracer-to-tracee ratio of HDL apoE increased slightly faster in diabetics than in non diabetics obese. Table 2 shows apoE levels and kinetic parameters in VLDL and HDL fractions. While plasma level and production rate of VLDL apoE were significantly higher in diabetic group, no significant difference was observed for the FCR of VLDL apoE. Ratios E=B-VLDL and E=TG-VLDL, representing the proportion of apoE relative to, respectively, apoB and TG content of VLDL, were calculated. Neither E=B-VLDL (35.9 AE 29.6 vs 40.7 AE 13.01), nor E=TG-VLDL (3.5 AE 3.79 vs 5.1 AE 1.7) were different between non-diabetic and diabetic obese. Plasma level and production rate of HDL apoE were also significantly higher for diabetics while its FCR was unchanged. We have calculated ratios E=AI-HDL, E=TG-HDL and E=Cholesterol-HDL, representing the proportion of apoE relative to, respectively, apoAI, TG and cholesterol content of HDL. While E=AI-HDL (14.9 AE 8.3 vs 6.7 AE 2.7, P ¼ 0.04) and E=Cholesterol-HDL (109 AE 119 vs 20 AE 11, P < 0.01) were significantly elevated in diabetics, E=TG-HDL was similar between the two groups (1.5 AE 0.9 vs 1.1 AE 0.4).
Relations of apoE kinetics and levels with parameters related to obesity and insulin resistance
In the whole population, relationships between apoE data and parameters related to obesity and insulin resistance are shown in Table 3 . BMI did not correlate with any of apoE kinetic parameters, HOMA correlated positively with the FCR of VLDL apoE and tended to be correlated with the APR of VLDL apoE (r ¼ 0.58, P ¼ 0.06). No correlation was found between HOMA and HDL apoE parameters. Hba1c correlated positively with level, APR and FCR of VLDL apoE and with APR and FCR of HDL apoE. Figure 1 Experimental values of the tracer-of-tracee ratio for VLDL (A) and HDL (B) apo E in non-diabetic (full square) an diabetic (empty square) obese subjects. Fits (lines) were calculated using monocompartmental analysis during a prime constant infusion of deuterium labelled leucine. Data are shown as mean AE s.e.m.
Influence of insulin resistance and diabetes on apolipoprotein E kinetics K Back-Ngohou et al As expected, plasma TG level correlated positively with plasma and VLDL apoE levels and tended to be correlated positively with APR and FCR of VLDL apoE (r ¼ 0.57 and 0.55, respectively, P ¼ 0.06). TG correlated positively with APR and FCR of HDL apoE but did not correlate with HDL apoE level. As expected too, VLDL apoB level, a marker of plasma TG pool at fasting state, correlated with plasma and VLDL apoE level, with APR and FCR of VLDL apoE and with APR and FCR of HDL apoE. Lipoprotein lipase activity correlated negatively with level of APR and FCR of VLDL apoE and with APR of HDL apoE.
Discussion
We have shown that diabetic obese subjects are characterized by elevated plasma VLDL and HDL apoE levels associated with enhanced VLDL and HDL apoE production rates. While BMI do not correlate with any of apoE kinetic parameters, HOMA and HbA1c are correlated with kinetic parameters of VLDL and HDL apoE. Our results suggest that, while obesity in itself may not interfere with apoE kinetic, parameters related to obesity, ie insulin resistance and glycemic control, may influence apoE metabolism of obese patients. This is the first time, to our knowledge, that apoE kinetic disorders in diabetic patients and that relation between insulin resistance, glycemic control and apoE metabolism have been shown. Simulated curves, obtained using SAAM II monocompartmental modelling to study VLDL and HDL apoE kinetics, fitted very well to experimental points, showing that the monocompartmental model was an appropriate one for the study of VLDL and HDL kinetics in our experimental conditions. This suggests that no apoE were exchanged between Values logtransformed. *P < 0.05, { P < 0.01, { P < 0.001. APR, absolute production rate; FCR, fractional catabolic rate.
Influence of insulin resistance and diabetes on apolipoprotein E kinetics K Back-Ngohou et al VLDL and HDL compartment through our infusion period. Accordingly, enrichment curves of VLDL apoE were completely different from those of HDL apoE, showing clearly that, in our study conditions, VLDL and HDL constituted two distinct pools of apoE and did not exchange together. Our results contrast with previous works showing that exchanges of apoE between lipoproteins occur rapidly both in vitro 36 and in vivo during lipolysis associated with post-prandial lipaemia. 12 However, in a fasting state, as in our protocol conditions, physiologic lipolysis may occur slowly, 37 leading thus to lower and undetectable quantities of apoE exchange between lipoproteins. Consistent with this hypothesis and with our results, Batal et al, 38 working with subjects in a fasting state, did not find any exchange between lipoproteins and concluded that VLDL and HDL represented kinetically distinct pool of apolipoproteins whereas Millar et al, 39 studying subjects at fed state and using multicompartmental model for apoE kinetics, have found apoE transfer from HDL to VLDL.
Studying VLDL apoE content of type 2 diabetic subjects are controversial, Taskinen et al 40 found no change in apoE relative to the apoB content of VLDL and a decreased apoE concentration compared with VLDL TG, Weisweiler et al 41 found an increased proportion of apoE in VLDL. Recently, we have found positive correlation between insulin levels and apoE TG-rich lipoproteins levels in hypertriglyceridaemic but not in the normotriglyceridaemic android obese. 22 We have shown that increased plasma VLDL apoE level of diabetic subjects was associated with the enhancement of its absolute production rate without any change of its catabolic rate. No change in apoE relative either to the apoB-or to the TG-content of VLDL was observed in NIDDM. As plasma VLDL-apoB and VLDL-TG were also increased in diabetic patients, enhancement of plasma VLDL-apoE seemed rather to be due to an increase in VLDL production than to an apoE enrichment of secreted VLDL. Increased VLDL apoE level could thus be a passive phenomenon, occurring simultaneously with the increase of VLDL particles. Accordingly, plasma VLDL-apoE was positively correlated with plasma VLDL-apoB and TG.
However, consistent with the hypothesis that apoE could be a strong inhibitor of LPL mediated lipolysis in TG-rich lipoproteins, 42, 43 we have found a negative correlation between LPL activity and both VLDL apoE level and kinetic parameters. In accordance with previous work, 21, 23, 30 we have also shown that LPL activity was significantly decreased in diabetic and insulin-resistant subjects. This should thus lead to a lower conversion of VLDL towards IDL. FCR of VLDL apoE results both from conversion of VLDL apoE towards IDL and from direct hepatic VLDL apoE clearance. In diabetic obese subjects, if apoE is normally recognized by its receptors, the lower LPL activity we have found associated with the unchanged FCR of VLDL apoE suggests an enhancement of apoE direct hepatic clearance. Therefore, FCR of VLDL apoE of diabetic obese could reflect two opposite effects: a less efficient conversion of VLDL to IDL and an accelerated clearance by the liver.
While insulin level did not correlate with apoE kinetic parameters, HOMA correlated positively with FCR and tended to be correlated with APR of VLDL apoE. This suggests that VLDL apoE metabolism could be related to the insulin resistant state rather than to the insulin effect in itself. However, the number of subjects is too low to draw definitive conclusions. As VLDL apoE is highly correlated with plasma and VLDL TG, it will be very interesting to thoroughly examine the relation between insulin level and apoE kinetics among a larger number of hypertriglyceridaemic subjects, even if recruitment of subjects for kinetic studies is limited by the complexity of the protocol used.
The strong relationships observed between HbA1c and all VLDL apoE parameters suggested that glycaemic equilibrium might also influence VLDL apoE kinetics. One possible explanation of the relation between HOMA and apoE data could be that insulin resistance, by increasing free fatty acid plasma level, enhances hepatic VLDL and thus VLDL apoE production. In response to this increased production, VLDL hepatic catabolism may be enhanced by apoE-specific receptor pathway or by another as yet undefined one. The stronger relation observed between HbA1c and apoE parameters could be due to the accentuation of such phenomenon during diabetes. Indeed, glycation of apoE or of another VLDL protein during the hyperglycaemic state may occur, leading to an enhanced turnover of VLDL and, thus, of VLDL apoE. Triglycerides plasma level, a reflection of free fatty acid plasma level, was strongly and positively correlated with plasma and VLDL apoE level. As hypertriglyceridaemia is characteristic of both insulin resistance and diabetes, we cannot exclude the observed strong relation between HOMA or HbA1c and apoE data resulting from the influence of hypertriglyceridaemia on apoE metabolism.
Concerning HDL, we have found an increased apoE level in obese diabetics, associated with an enhancement of its production rate. E=AI-HDL and E=Cholesterol-HDL ratios were significantly increased. As HDL apoAI and HDL cholesterol levels were unchanged, this suggests that in obese diabetics enhancement of HDL apoE production is associated with an enrichment of HDL particles with apoE. Many studies have now demonstrated that HDL apoE plays a crucial anti-atherogenic role. In vitro studies have shown that HDL apoE promotes cholesterol efflux from peripheral cells to the liver, 44 has a direct anti-atherogenic role at the site of atherosclerotic lesion, 45 has antioxidant activity 18 and inhibits platelet aggregation through the nitric oxide pathway. 46 In a previous work, we have also suggested that HDL apoE could play an anti-inflammatory role in vivo in obese adults. 47 Thus, apoE-enriched HDL could be a response of the organism against the important risk of atherosclerosis and coronary heart disease consecutive to insulin resistance and diabetic dyslipidemia. 5, 7, 23 We have found a positive relation between HDL apoE kinetics parameters and, respectively, plasma TG and VLDL apoB level, suggesting that Influence of insulin resistance and diabetes on apolipoprotein E kinetics K Back-Ngohou et al hypertriglyceridaemia and impaired VLDL metabolism could also be related to HDL apoE kinetics. Moreover, HbA1c positively correlated with both APR and FCR of HDL apoE, suggesting that glycaemic equilibrium could also strongly influence HDL apoE kinetics. It is also interesting to notice that the HDL apoE kinetic parameters we found were similar to those of Millar (multicompartmental model); 38 both parameters were lower than those described by Batal. 39 Concerning VLDL apoE, the parameters we found were largely lower than those of the non-obese studied in previously. 38, 39 Independently from the compartmental model used, the major differences between our three studies are the choice of the subject studied. Whereas Millar and the present authors studied subject aged of 40 -70 y (mean 60 -50 y), Batal studied younger subjects aged 30 y. If aging plays a role on apoE metabolism, this could explain the difference observed in HDL apoE parameters. Another important difference is the BMI of subject studied. We studied obese whereas Millar and Batal studied non-obese subjects; this may explain the great difference between VLDL apoE parameters and strengthen the hypothesis that parameters associated with obesity could influence apoE metabolism.
In summary, we have found that diabetic obese subjects are characterized by increased plasma VLDL and HDL apoE levels associated with their increased production rates. While obesity in itself may not interfere with apoE metabolism, parameters related to obesity, ie insulin resistance and glycemic equilibrium, could influence apoE kinetics. To go further in our investigations, it will be interesting to examine the influence of therapy correcting insulin resistance, dyslipidaemia related to insulin resistance or glycaemic disequilibria on apoE kinetics.
